WEKO3
アイテム
Impact of underlying liver etiology on post-hepatectomy survival outcomes in hepatocellular carcinoma patients
http://hdl.handle.net/10458/0002002208
http://hdl.handle.net/10458/000200220870525310-6222-4d60-a271-86e9493bec00
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Fulltext (349 KB)
|
.png)
|
| アイテムタイプ | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2026-01-19 | |||||||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||||||
| タイトル | Impact of underlying liver etiology on post-hepatectomy survival outcomes in hepatocellular carcinoma patients | |||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| キーワード | Metabolic dysfunction-associated steatotic liver diseases (MASLDs) | |||||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| キーワード | hepatectomy | |||||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| キーワード | hepatocellular carcinoma (HCC) | |||||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| キーワード | prognosis | |||||||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||||||
| 著者 |
七島, 篤志
× 七島, 篤志
WEKO
33886
× Arai, Junichi
× 今村, 直哉
WEKO
19941
× Hiyoshi, Masahide
× 土持, 有貴
WEKO
34900
× 和田, 敬
WEKO
35523
|
|||||||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||||||
| 内容記述 | Background: The underlying etiology of liver disease, such as metabolic dysfunction-associated steatotic liver diseases (MASLDs) or alcohol-related liver injury, significantly affects liver function and regenerative capacity. In hepatocellular carcinoma (HCC) patients undergoing hepatectomy, these background factors may influence postoperative outcomes and long-term survival. This study aimed to evaluate the impact of different etiologies of liver disease on survival outcomes following curative hepatectomy in patients with HCC. Methods: We retrospectively analyzed patients with HCC who underwent curative hepatectomy at two academic institutions. Background liver disease was classified according to etiology, including viral liver disease (VLD), alcohol-related liver disease (ALD), MASLD, and others. Survival outcomes were evaluated and compared across etiological groups at two institutions from 1994 to 2023. Results: Patients with VLD, ALD, and MASLD exhibited significantly elevated rates of advanced liver fibrosis (P<0.001), while vascular involvement was less frequent in MASLD cases. No significant differences in tumor stage, tumor markers, or postoperative complications were found among the etiologies. However, tumor recurrence was significantly more common in the VLD and ALD groups (P<0.001), and HCC-related deaths were most frequent in the VLD and other/unknown groups. MASLD patients presented the most favorable outcomes, with a 5-year recurrence-free survival (RFS) of 54% and a 10-year overall survival (OS) of 100%, significantly better than VLD (RFS 31%, OS 49%; P<0.01). Multivariate analysis revealed that VLD, vascular invasion, R1 margin, and poor liver function were independent predictors of recurrence and poor OS. Conversely, MASLD was not a significant risk factor for recurrence and was independently associated with better survival (P<0.05). Conclusions: MASLD-related HCC represents a distinct clinical entity with relatively indolent tumor behavior and better-preserved liver function. Recognizing the prognostic implications of MASLD-related HCC is essential for optimizing surgical indications and developing etiology-specific treatment strategies. |
|||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| 書誌情報 |
en : Translational cancer research 巻 14, 号 12, p. 8556-8566, 発行日 2025-12-31 |
|||||||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||||||
| 出版者 | AME Publishing Company | |||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| ISSN | ||||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||||||||||||||
| 収録物識別子 | 22196803 | |||||||||||||||||||||||||||||||||
| DOI | ||||||||||||||||||||||||||||||||||
| 関連タイプ | isVersionOf | |||||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.21037/tcr-2025-1809 | |||||||||||||||||||||||||||||||||
| 権利 | ||||||||||||||||||||||||||||||||||
| 権利情報 | © AME Publishing Company. | |||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||
| 著者版フラグ | ||||||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||||||
